|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||126.44 - 126.92|
|52 Week Range||99.60 - 133.00|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Incyte's 2Q17 revenue growth was driven by the increased demand for Jakafi.
Allergan reported an 8.8% increase in its 2Q17 revenues to $4.0 billion as compared to $3.7 billion in 2Q16.
In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.